NSCLC Stage IIIB

21 registered clinical trials studyying NSCLC Stage IIIB — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Exercise in Patients With Advanced Non-small Cell Lung Cancer NCT06374160	University Hospital, Essen	N/A
Withdrawn	A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC NCT05212922	Eucure (Beijing) Biopharma Co., Ltd	Phase 2
Terminated	Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer NCT05652868	Mythic Therapeutics	Phase 1
Active Not Recruiting	Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) NCT05816499	Shanghai Chest Hospital	Phase 1 / Phase 2
Recruiting	Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After S NCT05281406	Goethe University	Phase 2
Unknown	Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer NCT05132218	Peking University Cancer Hospital & Institute	—
Unknown	Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy NCT04467801	Jun Zhang, MD, PhD	Phase 2
Unknown	Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor NCT04932343	Samsung Medical Center	—
Recruiting	Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSC NCT04865250	University Hospital Heidelberg	Phase 2
Unknown	Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSC NCT04768491	Peking Union Medical College	—
Withdrawn	Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer NCT03628144	H. Lee Moffitt Cancer Center and Research Institute	Phase 2
Active Not Recruiting	Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients NCT04223596	Fundación GECP	Phase 2
Completed	A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squam NCT04042558	Centre Francois Baclesse	Phase 2
Active Not Recruiting	Phase 2 Study of Dacomitinib in NSCLC NCT04027647	National Cancer Centre, Singapore	Phase 2
Terminated	Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumo NCT03805841	Rain Oncology Inc	Phase 2
Active Not Recruiting	1st Line Durvalumab in PS 2 NSCLC Patients NCT03620669	Swiss Cancer Institute	Phase 2
Unknown	Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Pati NCT03647956	The University of Hong Kong	Phase 2
Unknown	Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A NCT03594682	Beijing Chest Hospital	N/A
Withdrawn	Phase I Study of SPH1188-11 in NSCLC NCT03231475	Shanghai Pharmaceuticals Holding Co., Ltd	Phase 1
Completed	Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer NCT03515252	Ivy Life Sciences, Co., Ltd	Phase 1
Completed	Chemoradiotherapy of NSCLC Stage IIIB NCT00198432	Intergroupe Francophone de Cancerologie Thoracique	Phase 2